Palantir discloses diluted share count, suggesting valuation north of $20 billion at high end

Palantir finally discloses diluted share count, suggesting valuation above $20 billion at high end

Palantir said in its third updated prospectus on Monday that it has 2.17 billion fully diluted shares, including over 250 million options and restricted stock units that haven't vested.

Palantir Technologies CEO Alex Karp arrives at the "Tech for Good" Summit in Paris, France May 15, 2019., Palantir finally disclosed a fully diluted share count, providing a total that includes some unvested options and restricted stock. However, the initial market cap likely won't reflect all of those shares because some terms haven't been satisfied for vesting of options and restricted stock units . Here's what Palantir says in a footnote of the filing:

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

CNBC /  🏆 12. in US

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

34 Things Under $20 That People Actually Swear BySome of these awesome are also under $10, and some are even under $5, so your wallet will be as happy with them as you are.
Weiterlesen »

20 Home Products Under $20 That'll Upgrade Your SpaceBig change for pocket change.
Weiterlesen »

Gilead Sciences to buy Immunomedics in over $20 billion dealThe two companies were initially discussing a future partnership before shifting to a takeover negotiation, The Wall Street Journal reported.
Weiterlesen »

Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Weiterlesen »

Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Weiterlesen »